October 24, 2016
Genotype 1 is the most common type of hepatitis C infection, accounting for nearly half of all cases in the world. A majority of genotype 1 infections appear in East Asia, the Americas and Europe. Genotype 1 also contains two prominent subtypes, called 1a and 1b, although most drugs approved today for genotype 1 can cure both subtypes with high success rates.
These drugs are combination regimens; some are packaged as one pill and some as multiple pills. Single-pill options include sofosbuvir/velpatasvir (Epclusa), elbasvir/grazoprevir (Zepatier) and sofosbuvir/ledipasvir (Harvoni). Patients can also take the multi-pill combo packed comprised of paritaprevir/ritonavir/ombitasvir and dasabuvir (Viekira Pak), or a combination of sofosbuvir (Sovaldi) with simeprevir (Olysio).
All of these options have excellent and highly comparable cure rates, so for genotype 1 patients the preferred option will likely come down to each patient's insurance plan and other mitigating factors, such as the presence of kidney disease or advanced liver disease, said Kevin Korenblat, M.D., professor of medicine, Division of Gastroenterology, Washington University School of Medicine in St. Louis.
Credit: naruedom for iStock via Thinkstock.
Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|No Increased Risk of Liver Cancer After Hepatitis C Treatment With Direct-Acting Antivirals|
|This Week in HIV Research: Another Person Possibly Cured of HIV; and Long-Acting Rilpivirine Suppresses HIV in Rectal Tissue|
|This Week in HIV Research: HIV-Related Inflammation May Be Irreversible; and Genetically Engineered T-Cells Resist HIV|
|How Close Are We to a Cure for HIV? A Q&A With HIV Cure Scientific Superstars|
|Dolutegravir and the Central Nervous System: A Top HIV Clinical Development of 2016|